STOCK TITAN
  1. Home
  2. News
  3. SAVA

Cassava Sciences Inc - SAVA STOCK NEWS

Welcome to our dedicated news page for Cassava Sciences (Ticker: SAVA), a resource for investors and traders seeking the latest updates and insights on Cassava Sciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cassava Sciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cassava Sciences's position in the market.

News
Redemption Date Announced for Warrants
Rhea-AI Summary
Cassava Sciences, Inc. announces the redemption date for warrants, with May 6, 2024, being the last day to exercise them. Holders will receive 1.5 shares of common stock per warrant, with a redemption price of $0.001 per warrant if not exercised by the deadline. The company urges holders to act promptly to avoid missing the deadline.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.04%
Tags
none
-
News
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
Rhea-AI Summary
Cassava Sciences, Inc. announces positive interim safety review of simufilam in Phase 3 trials for Alzheimer's disease treatment. DSMB recommends trials continue as planned. Final clinical safety data expected at program conclusion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.56%
Tags
clinical trial
-
News
Cassava Sciences Announces Virtual Presentation at the AD/PD™ 2024 International Conference
Rhea-AI Summary
Cassava Sciences to Present Oral Simufilam Data at AD/PD 2024 Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.13%
Tags
none
News
Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates
Rhea-AI Summary
Cassava Sciences, Inc. reported $121.1 million in cash and cash equivalents at December 31, 2023, with an additional $21.8 million raised in 2024. The company's Phase 3 studies have over 555 participants, with topline data readout expected year-end 2024. An internal investigation found no evidence of research misconduct. Net loss for 2023 was $97.2 million, with increased R&D and G&A expenses. Corporate highlights include dividend distribution, positive safety findings, new Board members, and biological activity confirmation of simufilam.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.3%
Tags
earnings
-
News
CASSAVA SCIENCES SHAREHOLDER ACTION REMINDER
Rhea-AI Summary
Faruqi & Faruqi, LLP is investigating potential claims against Cassava Sciences, Inc. for violating federal securities laws by allegedly making false statements regarding its drug research programs. The complaint alleges data manipulation in support of simufilam, leading to significant financial and reputational harm. Cassava's stock price fell 15.28% following reports of possible scientific misconduct by a researcher associated with the program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.75%
Tags
none
-
News
No Decline in Cognition Scores in Patients with Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months
Rhea-AI Summary
Cassava Sciences, Inc. reported top-line results of a two-year clinical safety study of simufilam, an investigational oral drug for the treatment of Alzheimer’s disease dementia. Patients with mild Alzheimer’s who received simufilam treatment continuously for two years had no decline in ADAS-Cog scores, while those who received non-continuous treatment declined by 1 point. Patients with moderate Alzheimer’s who received simufilam treatment continuously for two years declined 11.05 points on ADAS-Cog. The drug was safe and well-tolerated, with no drug-related serious adverse events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.35%
Tags
none
News
Cassava Sciences Completes Dividend Distribution of Warrants to Shareholders
Rhea-AI Summary
Cassava Sciences, Inc. (Nasdaq: SAVA) announced the completion of a distribution of warrants to its shareholders. The Warrants now trade on Nasdaq under the ticker SAVAW. Stockholders received four (4) Warrants for each ten (10) shares of the Company’s common stock held as of December 22, 2023 (the 'Record Date'). Each Warrant entitles the holder to purchase one share of Cassava Sciences’ common stock at an initial exercise price of $33.00 per share, with the option of receiving an additional 0.5 of a share per Warrant through the Bonus Share Program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.45%
Tags
dividends
-
News
Cassava Sciences Announces Dividend Distribution of Warrants to Shareholders
Rhea-AI Summary
Cassava Sciences, Inc. (Nasdaq: SAVA) announces pro rata dividend distribution of warrants to shareholders of record. Shareholders will receive 4 warrants for every 10 shares held as of December 22, 2023. Warrants are expected to list and trade on Nasdaq. Warrant holders who choose to exercise during an early period will also receive an additional 0.5 of a common share per warrant.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.96%
Tags
dividends
-
News
Cassava Sciences Appoints Three New Members to its Board of Directors
Rhea-AI Summary
Cassava Sciences, Inc. (Nasdaq: SAVA) appoints three new board members with extensive experience in drug development, healthcare M&A, and cybersecurity. Dr. Nicaise has 14 new drug approvals, Mr. Gravier is a CFO of a biotech company, and Mr. Anderson has operational experience in cybersecurity and counterintelligence.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.37%
Tags
management
News
Cassava Sciences Reports Third Quarter 2023 Financial and Operating Results
Rhea-AI Summary
Cassava Sciences, Inc. completed enrollment for Phase 3 trials evaluating oral simufilam in Alzheimer's, with over 1,900 patients randomized. Top-line results for the 52-week Phase 3 trial expected approximately year-end 2024, and for the 76-week Phase 3 trial expected approximately mid-year 2025. MRI safety data suggests simufilam is not associated with ARIA. The company reported $142.4 million in cash and cash equivalents at September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.3%
Tags
earnings
Stock SAVA logo
Cassava Sciences Inc

Nasdaq:SAVA

SAVA Rankings

#2456 Ranked by Market Cap
#4524 Ranked by Stock Gains
N/A Ranked by Dividends

SAVA Stock Data

983.84M
40.20M
7.17%
32.7%
27.26%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Austin

About SAVA

refer to descriptions included in the company's filings with the securities and exchange commission for more information about the company. the company does not intend to update and does not take responsibility for any information published on linkedin.